danvatirsen + durvalumab + tremelimumab

This drug is a combination of **danvatirsen** (an antisense oligonucleotide targeting STAT3), **durvalumab** (a monoclonal antibody against programmed death-ligand 1 / PD-L1), and **tremelimumab** (a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 / CTLA-4). Danvatirsen inhibits STAT3, a transcription factor linked to tumor growth and immune evasion. Durvalumab blocks PD-L1, reactivating T-cell anti-tumor immunity. Tremelimumab blocks CTLA-4, another checkpoint inhibitor that suppresses immune responses. The combination aims to augment endogenous antitumor activity by targeting different complementary immune pathways[1].